Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9120286 | 0.78 | POLB (0.36) | POLBPTGS2ALDH1A1L3MBTL1 | |
| SCHEMBL21846831 | 0.78 | CRBN (0.34) | POLBALDH1A1L3MBTL1 | |
| SCHEMBL23028988 | 0.77 | POLB (0.32) | POLB | |
| SCHEMBL5310918 | 0.75 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL12128675 | 0.73 | ADORA2B (0.31) | — | |
| SCHEMBL19377760 | 0.71 | GSK3B (0.46) | ALDH1A1 | |
| SCHEMBL16352665 | 0.69 | ALDH1A1 (0.46) | POLBALDH1A1 | |
| SCHEMBL29736746 | 0.69 | GSK3A (0.42) | POLBALDH1A1L3MBTL1 | |
| SCHEMBL11317932 | 0.68 | PTGS2 (0.49) | PTGS2ALDH1A1L3MBTL1 | |
| SCHEMBL7519636 | 0.67 | KMT2A (0.52) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-8846638-B2 | Macrocyclic nucleoside phosphoramidate derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY (CA) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | POLB 1012/4885PTGS2 176/4885ALDH1A1 982/4885 |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | NUDT1, DPYD, TYMP | POLB 1115/4885PTGS2 958/4885ALDH1A1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.